Positive Patient Stories™

Investor Overview

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$17.75
Change (%) Stock is Up 0.10 (0.57%)
Volume144,985
Data as of 12/12/17 10:23 a.m. ET

Latest News

12/01/17
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
11/08/17
Paratek Pharmaceuticals Reports Third Quarter 2017 Financial Results, Remains on Track to Complete NDA Submissions in First Quarter of 2018
11/01/17
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
10/24/17
Paratek Pharmaceuticals to Report Third Quarter 2017 Financial Results and Provide Update on Clinical Progress on November 8, 2017
See More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.